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Molecular MR Imaging for Visualizing
ICAM-1 Expression in the Inflamed
Synovium of Collagen-Induced Arthritic
Mice
Objective: To determine the utility of intercellular adhesion molecule (ICAM)-1
antibody-conjugated gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA-
anti-ICAM-1) as a targeted contrast agent for the molecular magnetic resonance
imaging (MRI) in collagen-induced arthritis (CIA). 
Materials and Methods: Three groups of mice were used: non-arthritic normal,
CIA mice in both the early inflammatory and chronic destructive phases. The MR
images of knee joints were obtained before and after injection of Gd-DTPA-anti-
ICAM-1, Gd-DTPA, and Gd-DTPA-Immunoglobulin G (Ig G) and were analyzed
quantitatively. The patterns of enhancement on the MR images were compared
with the histological and immunohistochemical ICAM-1 staining. 
Results: The images obtained after injection of Gd-DTPA-anti-ICAM-1 dis-
played gradually increasing signal enhancement from the moment following injec-
tion (mean ± standard deviation [SD]: 424.3 ± 35.2, n = 3) to 24 hours (532 ±
11.3), rather than on pre-enhanced images (293 ± 37.6) in the early inflammato-
ry phase of CIA mice. However, signal enhancement by Gd-DTPA and Gd-
DTPA-IgG disappeared after 80 minutes and 24 hours, respectively. In addition,
no significant enhancement was seen in the chronic destructive phase of CIA
mice, even though they also showed inflammatory changes on T2-weighted MR
images. ICAM-1 expression was demonstrated in the endothelium and proliferat-
ing synovium of the early inflammatory phase of CIA mice, but not in the chronic
destructive phase. 
Conclusion: Molecular MRI with Gd-DTPA-anti-ICAM-1 displays specific
images targeted to ICAM-1 that is expressed in the inflamed synovium of CIA.
This novel tool may be useful for the early diagnosis and differentiation of the vari-
ous stages of rheumatoid arthritis. 
heumatoid arthritis (RA) is a chronic inflammatory disease, and affected
individuals experience significant morbidity, including loss of function,
joint destruction, and permanent deformity, in addition to having a
higher mortality than the general population (1). Molecular imaging techniques that
use targeted agents binding specifically to inflamed synovium are increasingly allowing
earlier diagnoses and assessment of a treatment response in RA (2-4). Several studies
have shown that it is possible to target and visualize specific cellular processes in
arthritic synovium using molecular imaging approaches (5-8). However, these studies
are currently limited to nuclear and optical imaging methods in RA. In addition,
magnetic resonance imaging (MRI) has not been used despite its particular advantage
of simultaneously showing information at the anatomical and molecular levels. 
The vascular endothelium is an attractive target for imaging and therapy in RA due
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Rto its obvious accessibility through the systemic circulation
(4-6, 9). The intercellular adhesion molecule (ICAM)-1 is
primarily found on synovial endothelial cells and helps
recruit lymphocytes, monocytes, and neutrophils to the
joints in RA (10-12). ICAM-1 also plays a role in the
interactions between activated lymphocytes, fibroblast-like
synoviocytes, and macrophage-like synoviocytes in the
synovial lining and sublining (12-14). In addition, the
immunohistochemical ICAM-1 findings were different for
various stages of RA (15), and the potential therapeutic
roles of anti-ICAM-1 agents have also been studied in
several animal models of inflammatory arthritis and
patients with RA (16-18). Thus, ICAM-1 represents a
promising molecular target in specific targeted molecular
imaging, drug delivery, and tissue engineering for patients
with RA. 
In a previous study, we produced ICAM-1 antibody-
conjugated gadolinium diethylenetriaminepentaacetic acid
(Gd-DTPA-anti-ICAM-1) as an inflammatory cell-targeted
MR contrast agent, which was prepared by bioconjugating
Gd-DTPA and anti-ICAM-1. We confirmed that a molecu-
lar MRI using the Gd-DTPA-anti-ICAM-1 display targeted
T1 MR images specific to ICAM-1 in the mouse abscess
model (19). However, to date, no studies that utilize
ICAM-1 as a candidate target for molecular MR imaging
have been performed in the field of RA. Thus, the current
study was designed to evaluate the utility of Gd-DTPA-
anti-ICAM-1 as a targeted contrast agent for molecular
MRI with a conventional 1.5 Tesla MR machine to
diagnose and distinguish different stages of collagen-
induced arthritis (CIA). 
MATERIALS AND METHODS
Generation of Gd-DTPA-anti-ICAM-1 and 
Gd-DTPA-IgG 
Bioconjugation of both the anti-ICAM-1 antibody and
rat IgG (Sigma, St. Louis, MO) to diethylenetriamine
pentaacetic acid bisanhydride (DTPABA) and gadolinium
chloride (GdCl) was performed according to a previously
described procedure (19). Briefly, the anti-ICAM-1
antibody was purified from the culture supernatant of rat
hybridoma using protein A/G-coupled affinity chromatog-
raphy. The anti-ICAM-1 antibody and rat IgG (control)
were conjugated to DTPABA in PBS (pH 8.5) for 1 hour at
room temperature. GdCl was dissolved in deionized water
and added to the DTPA-antibody conjugate solution. One
part of the DTPA-antibody complex was then combined
with 40 parts of GdCl in 0.5 M sodium acetate (pH 5.5).
The molar ratio of Gd to antibody was about 1:20 in
quantitative analysis using ICP-MS (Agilent 7500A, Palo
Alto, CA). The Gd-conjugated antibodies did not show any
cytotoxic effect on the cultured endothelial cells. The
calculated plasma half-life of the Gd-DTPA-antibody
conjugate was 3.6 ± 0.16 hours, which is, in turn, ten
times longer than that of Gd-DTPA (~20 min). The
measured relaxivity (mmol-1sec-1) of the Gd-DTPA-anti-
ICAM-1 (23.27 ± 1.31) was higher than that of Gd-DTPA
(6.55 ± 0.58) as measured on a 1.5 Tesla MR scanner. 
Animals and CIA Induction
Male DBA/1J mice, 7-9 weeks of age and free of
murine-specific pathogens, were purchased from Orient
(Seoul, Korea), housed throughout the experiments in a
laminar flow cabinet. To induce CIA, mice were
immunized intradermally at the base of the tail with 100 μ
g of bovine type II collagen (CII; Chondrex, Redmond,
WA) emulsified in an equal volume of complete Freund
adjuvant (Chondrex). Three weeks later, the mice were
boosted in the same manner. The day of the first injection
of CII was considered day 0 for all mice. All animal
procedures were conducted with approval from our
Institutional Animal Care and Use Committee.
Study Design
We used three groups of mice: normal non-arthritic mice
(n = 3); mice in the early inflammatory phase of CIA (day
28, 4 weeks after 1st injection, n = 9); and mice in the
chronic destructive phase of CIA (day 56, 8 weeks after 1st
injection, n = 3). Prior to all MR imaging, all experimental
mice were sedated by an intramuscular injection of 10
mg/kg of ketamine hydrochloride (Ketalar; Yuhan
Yanghang, Seoul, Korea) in combination with 10 mg/kg of
xylazine hydrochloride (Rumpun; Bayer Korea, Seoul,
Korea). For MR imaging, T2-weighted fat-suppressed
images were obtained before injecting contrast agents to
evaluate the presence or absence of synovitis in the
individual knee joints in all experimental mice. A T1-
weighted dynamic MR imaging was then performed prior
to and immediately after, as well as 10 minutes, 30
minutes, 80 minutes, 2 hours, and 24 hours after bolus
injection of contrast agents into the tail vein. All nine
experimental mice belonging to the early inflammatory
phase of CIA group were analyzed, with three mice each
receiving one of three types of MR contrast agents as
follows: Gd-DTPA (100 nmoles of Gd/gm of body weight)
as a non-targeted contrast agent, Gd-DTPA-anti-ICAM-1
(10 nmoles of Gd/gm of body weight) as a targeted
contrast agent, and Gd-DTPA-IgG (10 nmoles of Gd/gm of
body weight) as a control contrast agent. A T1-weighted
dynamic MRI using Gd-DTPA-anti-ICAM-1 was also
performed in the normal non-arthritic and chronic destruc-
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radiographs were obtained to assess joint destruction using
a full-field digital mammography system. Following the
MRI, the mice were sacrificed by cervical dislocation to
collect the knee joints for histopathologic and immunohis-
tochemical analysis.  
MRI and Analysis
After sedation, the mice were placed in the prone
position with their hind legs fixed to a plate with an
adhesive bandage. All the in vivo MR images of CIA mice
were obtained with a 1.5 Tesla clinical MR machine
(Magnetom Symphony, Siemens Medical Systems,
Erlangen, Germany). To maximize the signal-to-noise
ratio, mice were placed with their knees below a small
loop coil (diameter 5 cm) provided by the manufacturer.
The fat-suppressed, coronal MR images were obtained
before and after the intravenous injection of Gd-DTPA
(Magnevist, Bayer HealthCare Pharmaceuticals, Wayne,
NJ), Gd-DTPA-IgG, and Gd-DTPA-anti-ICAM-1. 
Imaging protocols for both the pre-contrast and post-
contrast MR studies included the following sequences: fat-
suppressed T1-weighted fast spin echo (FSE) (repetition
time msec/echo time msec, 300/14; field of view, 42 × 56
mm; matrix dimension, 256 × 154), and fat-suppressed
T2-weighted FSE (1700/103; echo train length, 15; field of
view, 42 × 56 mm; matrix dimension, 256 × 154). The
T1- and T2-weighted FSE images had the same sagittal
positioning. The image sections were 2.0 mm thick for T1-
and T2-weighted FSE images. An MRI was performed in
the sagittal planes for all sequences. 
For the quantitative analysis, signal intensity was
measured on serial MR images using a region of interest
(ROI) that was identified by two radiologists blinded to the
grouping of the mice. One circular ROI with a diameter
between 2 and 5 mm
2 was placed in the same location of
knee joints, and included high signal intensity areas, which
were regarded as the synovial membrane, synovial fluid,
and joints capsules. Discrepancies for the selection of ROIs
were resolved by mutual consensus.
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Fig. 1. MR images of knee joints in early inflammatory phase of collagen-induced arthritis mice. A. Gd-DPTA-injected; B. Gd-DPTA-anti-
ICAM-1-injected; and C. Gd-DPTA-IgG-injected mice. In first column (far left), T2-weighted fat-suppressed MR images of arthritic knees
of collagen-induced arthritis mice demonstrate thickened synovium and joint effusion as area of hyper-intense signal. Second column
shows pre-contrast images; following columns (left to right) show dynamic T1-weighted MR images acquired immediately, 10 minutes,
30 minutes, 80 minutes, 2 hours, and 24 hours after injection of contrast agents. Quick T1 enhancement with Gd-DTPA was
demonstrated immediately after injection and disappears after 80 minutes (A). MR images with Gd-DTPA-anti-ICAM-1 display gradually
increasing signal enhancement in arthritic knee for 24 hours after injection of this targeted contrast agent (B). Signal enhancement with







10 min 30 min 80 min 2 hr 24 hrEx Vivo Radiographic Imaging Using Mammography 
After the hind limbs were removed, the legs were fixed
in formalin for radiographic imaging. The plain radiographs
of the knee joints were obtained using a mammographic
imager based on a direct detection flat panel array design
(Mammomat NovationDR, Siemens Medical Solutions,
Erlangen, Germany). A full field flat panel digital detector
measuring 24 cm × 29 cm (maximum matrix size, 3328×
4096; pixel size, 70 μ m) was used. All images were
obtained using exposure settings of 30 kVp and 90 mAs
and taken with a 1.5X magnification.
Histopathologic and Immunohistochemical
Examination
The animals were sacrificed, and the knees were taken to
be fixed in 10% neutral buffered formalin overnight and
decalcified with Calci-Clear Rapid (Diagnostics, Atlanta,
GA) overnight. The knees were embedded with paraffin,
and the tissues were sliced into 5 μ m sections for
Hematoxylin and Eosin (H & E) as well as immunohisto-
chemical staining. Anti-ICAM-1 polyclonal antibody (BD
biosciences, San Jose, CA) was used for immunohisto-
chemical staining.
RESULTS
ICAM-1-Targeted Molecular MR Imaging with Gd-
DTPA-anti-ICAM-1 in the Early Inflammatory Phase
of Collagen-Induced Arthritis Mice
The ICAM-1-targeted molecular MR images using Gd-
DTPA-anti-ICAM-1 as a targeted contrast agent were
examined in the early inflammatory phase of CIA mice
(Fig. 1). First, T2-weighted fat-suppressed MR images of
arthritic knee joints demonstrated synovial thickening and
joint effusion as an area of hyper-intense signal in all mice
in the early inflammatory phase of CIA. When pre- and
post-enhanced T1-weighted images were compared, the
quick T1 enhancement was shown immediately after
injection of Gd-DTPA as a non-targeted contrast agent,
which persisted for only a few minutes, and completely
disappeared within 80 minutes in the arthritic knee (Fig.
1A). In contrast, dynamic MR images with Gd-DTPA-anti-
ICAM-1 found the synovial enhancement to increase
gradually and persist for 24 hours after injecting this
ICAM-1-targeted contrast agent (Fig. 1B). Interestingly,
although the Gd content of the Gd-DTPA-anti-ICAM-1
was almost ten times lower than that of Gd-DTPA, a signif-
icant T1 enhancement of inflamed synovium was observed
in MR images with the Gd-DTPA-anti-ICAM-1. However,
the dynamic MR images with Gd-DTPA-IgG, which was a
Gd-conjugated control antibody with the same amount of
Gd as the Gd-DTPA-anti-ICAM-1, showed signal enhance-
ment for only 30-60 minutes. Moreover, this T1 enhance-
ment disappeared within 24 hours (Fig. 1C). In addition,
MR images in Figure 1 show well-preserved joints in the
arthritic knees in all the early inflammatory phases of CIA
mice. 
Figure 2 reflects quite different patterns of the enhance-
ment curves of these three kinds of contrast agents follow-
ing the quantitative analysis of signal enhancement in the
early inflammatory phase of CIA mice. T1 enhancement
(mean ± standard deviation [SD]: 393.0 ± 49.1, n = 3)
was demonstrated immediately after injecting Gd-DTPA
(100 nmoles of Gd/gm of body weight), compared to pre-
enhanced images (212.3 ± 35.4) and decreased T1
enhancement at 80 minutes (254.7 ± 20.2) in the early
inflammatory phase of CIA mice. However, Gd-DTPA-
anti-ICAM-1 (10 nmoles of Gd/gm of body weight)
enhanced images display gradually increasing signal
enhancement from immediately following injection (mean
± SD: 424.3 ± 35.2, n = 3) to 24 hours (532.0 ± 11.3)
after injection of the targeted contrast agent compared to
pre-enhance images (293 ± 37.6). Moreover, the MR
images with Gd-DTPA-IgG show signal enhancement for
only 30-60 minutes after injection of contrast agent
compared to pre-enhance images (307 ± 19.7), which
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Fig. 2. Comparisons of mean enhancement curves in early
inflammatory phase of collagen-induced arthritis mice injected
with Gd-DTPA (n = 3), Gd-DTPA-anti-ICAM-1 (n = 3), or Gd-
DTPA-IgG (n = 3) at different times. 
Quick T1 enhancement (mean ± SD: 393.0 ± 49.1, n = 3) was
demonstrated immediately after injecting Gd-DTPA (100 nmoles
of Gd/gm of body weight) compared to pre-enhanced images
(212.3 ± 35.4) and decreased at 80 minutes (254.7 ± 20.2). Gd-
DTPA-anti-ICAM-1 enhanced images display gradually increas-
ing signal enhancement from immediately (mean ± SD: 424.3 ±
35.2, n = 3) to 24 hours (532.0 ± 11.3) compared to pre-
enhanced images (293 ± 37.6). MR images with Gd-DTPA-IgG
show signal enhancement only for 30-60 minutes after injection
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Gd-DTPA-anti-ICAM-1
Gd-DTPA
Gd-DTPA-IgGfades away within 24 hours (297 ± 7.6). The Gd-DTPA-
IgG enhancement patterns of all three CIA mice, in the
early inflammatory phase, were also similar, although the
size of the synovial inflammatory area varied. In addition,
the results of the quantitative analysis of signal enhance-
ment were in accordance with the calculated plasma half-
life of Gd-DTPA-antibody conjugate (3.6 ± 0.16 hours),
which is ten times longer than that of Gd-DTPA (~20
minutes).
Distinguishing Different Stages of Collagen-Induced
Arthritis by Molecular MRI with Gd-DTPA-anti-
ICAM-1 
ICAM-1-targeted molecular MR images using Gd-DTPA-
anti-ICAM-1 were also examined in the chronic destructive
phase of CIA mice. Moreover, T2-weighted fat-suppressed
MR images of arthritic joints demonstrated synovitis and
joint destruction. However, very little to no signal
enhancement was observed in arthritic knees up to 24
hours after injection of Gd-DTPA-anti-ICAM-1, compared
with mice in the early inflammatory phase of CIA (Fig. 3).
The patterns of enhancement curves following the quanti-
tative analysis of signal enhancement of all three CIA mice
in the chronic destructive phase were also similar (Fig. 4).
In Figure 5, no signal enhancement was observed in the
T1-weighted MR images of non-arthritic normal knee
joints up to 12 hours after injection of Gd-DTPA-anti-
ICAM-1. Also, plain film, H & E and immunohistochemical
staining for ICAM-1 showed normal findings (Fig. 5A). The
significant signal enhancement following the injection of
Gd-DTPA-anti-ICAM-1 was noted in arthritic knee joints
of early phase CIA mice (Fig. 5B). The joint of this early
inflammatory phase of CIA mice demonstrated the marked
inflammatory changes on T2-weighted MR images and
marked synovial hyperplasia on H & E staining. The
evidence of bone destruction was not observed on plain
radiograph and H & E staining. Dense ICAM-1 expression
is shown in the endothelium and is reduced in the subinti-
Lee et al.
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Fig. 4. Comparison of mean enhancement curves between early
(n = 3) and chronic (n = 3) phases of collagen-induced arthritis in
mice injected with Gd-DTPA-anti-ICAM-1 at different times. MR
images obtained from mice in chronic destructive phase of
collagen-induced arthritis, after injection of Gd-DTPA-anti-ICAM-
1, show no significant signal enhancement for up to 24 hours.
CIA = collagen-induced arthritis 
Fig. 3. MR images with Gd-DTPA-anti-
ICAM-1 of knee joint of mouse in
chronic destructive phase of collagen-
induced arthritis.
A. T2-weighted fat-suppressed MR
image demonstrates synovitis and
destruction of knee joints (arrows).
B. Image obtained before injection. 
C-H. T1-weighted serial MR images
obtained immediately, 10 minutes, 30
minutes, 1 hour, 2 hours, and 24 hours
after Gd-DTPA-anti-ICAM-1 injection.
Very little to no signal enhancement is
observed in arthritic knee joints for up to
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Early phase of CIA
Chronic phase of CIAmal layer of the proliferating synovium of mice in this
early inflammatory phase of CIA. However, the ICAM-1-
targeted synovial enhancement was not observed in the
chronic destructive phase of CIA mice, even though they
also showed inflammatory changes on T2-weighted MR
images (Fig. 5C). Severe pannus invasion and bone
destruction were observed on H & E staining and plain
radiograph, but little to no ICAM-1 expression was
observed in the synovium of the chronic destructive phase
of CIA mice. 
DISCUSSION
ICAM-1 is a promising target for the molecular imaging
of RA. We demonstrated that Gd-DTPA-anti-ICAM-1 can
be targeted to ICAM-1 that is expressed in the inflamed
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Fig. 5. MR images, plain films, as well as histopathological and immunohistochemical findings in A. non-arthritic normal mouse; B. early
inflammatory phase; and C. chronic destructive phase of collagen-induced arthritis mice. In first column, T2-weighted fat-suppressed MR
images show hyper-intense signals in arthritic joints in early inflammatory (B) and chronic destructive phases (C) of collagen-induced
arthritis. In second column, ICAM-1-targeted T1-weighted MR images significant signal enhancement was demonstrated uniquely in
mouse in early inflammatory phase of collagen-induced arthritis (B). In third column, only mouse in chronic destructive phase of collagen-
induced arthritis showed bone erosion (arrows) under plain radiographs (C). Hematoxylin & Eosin staining (fourth column) shows
synovial hyperplasia (asterisks) in early inflammatory phase of collagen-induced arthritis (B) as well as marked pannus invasion and
bone destruction (arrowheads) in chronic destructive phase of collagen-induced arthritis (C). In last column, dense ICAM-1 expression is





�synovium of mice in the early inflammatory phase of CIA.
Notably, this is the first study to identify the utility of
targeted molecular MRI in the RA research field. We also
showed that molecular MRI with Gd-DTPA-anti-ICAM-1
can differentiate the early inflammatory phase of CIA from
the chronic destructive phase. Our observation shows the
possibility of using Gd-DTPA-anti-ICAM-1 as a direct
cellular targeting contrast agent in the molecular MRI for
RA.
Monoclonal antibodies have limitations such as an
increased circulating half-life and the human anti-mouse
antibody response, although they have greater specificity
for antigens as molecular imaging agents than conventional
non-specific imaging agents. These shortcomings can
produce increased background (blood pool) activity and
may interfere with biospecificity (20). In our study, there
are good reasons to conclude that the significant signal
enhancement on MR images reflects the targeted ICAM-1
binding of Gd-DTPA-anti-ICAM-1 rather than both the
unbound and the non-specifically bound fractions of this
agent. First, on the MR images with Gd-DTPA-anti-ICAM-
1, the T1 enhancement gradually increased and lasted for
24 hours (several times longer than the half-life of this
ICAM-1-targeted contrast agent) in the arthritic joints of
CIA mice. In contrast, T1 enhancement was shown
immediately following the injection of Gd-DTPA as a non-
targeted contrast agent, however lasted for only a few
minutes. Also, the dynamic MR images with Gd-DTPA-
IgG, Gd-conjugated control antibody with the same
amount of Gd as the Gd-DTPA-anti-ICAM-1 demonstrated
signal enhancement for only 30-60 minutes after the
injection of contrast agent. Second, although the Gd
content of the Gd-DTPA-anti-ICAM-1 was almost ten
times lower than that of Gd-DTPA, a marked amount of
T1 enhancement by this ICAM-1 targeted contrast agent
was observed. Third, the signal enhancement by Gd-
DTPA-anti-ICAM-1 on MR images and ICAM-1 expres-
sion on synovium, were observed in only the early inflam-
matory phase of CIA mice, but not in the chronic destruc-
tive phase. Thus, we concluded that prolonged signal
enhancement on our MR images using Gd-DTPA-anti-
ICAM-1 is a consequence of targeted binding to ICAM-1 in
inflamed synovium. 
Gd-DTPA is a non-specific contrast agent that is
commonly used for MRI of hemodynamic parameters,
including blood perfusion and vascular permeability (21).
In contrast, Gd-DTPA-anti-ICAM-1 is a specific MR
contrast agent that can be targeted to ICAM-1 and can thus
identify specific cellular or molecular events that underlie
disease. Gd-DTPA is transported in the plasma and diffuses
freely throughout the interstitial space, but it is imperme-
able to the plasma membrane. In addition, it is excluded
from cells and remains extracellular. This non-specific
contrast agent accentuates differences in permeability or
perfusion and is helpful in characterizing physiological
processes, such as blood volume, flow, and perfusion (21).
In RA, the inflamed synovium shows a large number of
capillaries, enhanced capillary perfusion, and permeability.
Thus, Gd-DTPA allows for the differentiation of the
inflamed synovium from both surrounding healthy tissue
and normal synovium through a marked increase of signal
intensity on T1-weighted MR images (22-24). However,
this contrast agent is nonspecific and does not provide any
information regarding cellular and molecular mechanisms.
Importantly, synovitis in RA is characterized by angiogen-
esis, cellular infiltration, and the production of various
cytokines and adhesion molecules. While Gd-DTPA can
only estimate blood perfusion and vascular permeability,
Gd-DTPA-anti-ICAM-1 may enable the non-invasive
evaluation of cellular and molecular changes, which often
occur before any signs of pathologic and anatomical
changes in the course of RA. 
To our knowledge, this is the first report that identifies
the utility and possible applicability of a targeted molecular
MRI in the field of research for RA. Moreover, a conven-
tional 1.5 Tesla MR machine, which is widely used in
clinical practice, was used in our study. MRI has been
regarded as a powerful imaging tool because of its
noninvasive nature, high spatial resolution, and
tomographic capabilities. In addition, MRI can visualize
bone erosions much better than conventional radiography
in the early stage of RA. Thus, MRI has been increasingly
used to evaluate the joints of RA patients (25). The
development of targeted MR contrast agents could dramat-
ically expand the range of MR applications by combining
the noninvasiveness and high spatial resolution of MRI
with specific localization of molecular targets (21). Several
successful attempts with various molecular targets and
specific MR agents have been reported in the field of
tumor imaging (26-29). However, MRI has not been used
for studies using molecular imaging agents in RA, as these
studies are currently limited to nuclear and optical imaging
methods (3). The full MR imaging examination can be a
lengthy procedure, and its low signal sensitivity has been a
major limitation in experimental molecular imaging (24).
Our study used Gd-DTPA-anti-ICAM-1, which has several
unique characteristics including a higher conjugation ratio
of Gd/antibody (1:20), a much longer plasma half-life (ten
times longer than that of Gd-DTPA), and greater relaxitiv-
ity (two times higher than that of Gd-DTPA) as mentioned
in a previous report (16). Therefore, a significant amount
of T1 enhancement was obtained in the dynamic molecular
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mental molecular imaging method. Limitations of our
study include small sample size, no definite discrimination
between synovial fluid and targeted synovium, and the
absence of an ICAM-1 Ab-blocking study. Thus, further
studies are needed to clarify the usefulness of molecular
MRI using Gd-DTPA-anti-ICAM-1 as guidance for the
ICAM-1 targeted diagnosis and a marker of therapeutic
response in clinical practice. 
In conclusion, this study demonstrates that Gd-DTPA-
anti-ICAM-1 can be targeted to ICAM-1 expressed in the
inflamed synovium during the early inflammatory phase of
CIA mice. Thus, our results clearly show the feasibility of
using Gd-DTPA-anti-ICAM-1 as a specific contrast agent
for molecular MRI that targets ICAM-1 expressed in the
inflamed synovium of CIA, the most reliable model of
human RA. In RA, this novel tool may be used to evaluate
pathophysiological processes, facilitate early diagnosis, and
monitor therapy.  
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